Issue Brief
  1. While all low- and middle-income countries of COVAX are eligible to receive technical assistance and cold chain equipment, priority will be given to Gavi-eligible countries.

    ← Return to text

  2. Of the committed countries, 29 European countries have joined through the European Commission.

    ← Return to text

  3. Team Europe, comprised of 29 countries, is excluded from the counts of self-financing participants’ agreement structures.

    ← Return to text

  4. AMC countries may receive additional doses to vaccinate more than 20% of their populations but must provide funds through a tiered cost-sharing obligation for these additional amounts. India, because of its large population, has a unique agreement with COVAX to receive enough doses to cover only 7-9% of its population.

    ← Return to text

  5. Not all vaccine candidates receiving CEPI funding have an agreement with COVAX to supply COVID-19 vaccine doses. Only 6 of the 11 candidates contain supply of COVID-19 vaccine doses as part of their funding agreements: AstraZeneca, Clover Biopharmaceuticals, CureVac, Novavax, SK Bioscience, and University of Queensland/CSL. However, CEPI recently announced that the University of Queensland/CSL vaccine candidate would not be continued beyond the Phase I trial.

    ← Return to text

  6. For a vaccine candidate to be distributed through COVAX, the candidate must be on the WHO Emergency Use or Prequalification list or receive approval from a limited set of country-specific regulatory authorities. These regulatory authorities include the Therapeutic Goods Administration (Australia), European Medicines Agency (EU), Health Canada (Canada), Swissmedic (Switzerland), Medicines and Healthcare products Regulatory Agency (UK), or U.S. Food and Drug Administration (U.S.).

    ← Return to text

  7. COVAX has an agreement with Serum Institute of India to provide an additional 900 million doses of either the AstraZeneca or Novavax vaccine.

    ← Return to text

  8. COVAX has right of first refusal access to candidates funded by CEPI. These candidates are estimated to provide 1 billion doses.

    ← Return to text

  9. Cold chain storage support will be available to the 56 Gavi-eligible participants and India. The remaining 35 AMC participants may be eligible based on need and available funding.

    ← Return to text

  10. The 3% mark was determined by the WHO as the approximate proportion of health care workers within countries’ populations.

    ← Return to text

  11. The additional 17%, summing to the 20% mark, is an approximation by the WHO for countries to be able to vaccinate their high-risk populations, such as older adults and individuals with underlying health conditions.

    ← Return to text

  12. In the framework, a country’s threat level will be assessed based on the spread of COVID-19 in the country and presence of other influenza viruses. A country’s vulnerability level will be assessed based on its health systems capacity according to the universal health coverage index and occupancy of hospital beds.

    ← Return to text

  13. According to the SAGE Prioritization Roadmap, this group may include individuals with comorbidities and economically disadvantaged groups. The Roadmap also acknowledges the need for variation in priority groups among countries.

    ← Return to text

  14. This total excludes payments from the 29 countries included in Team Europe.

    ← Return to text

  15. Additionally, at the end of 2020, COVAX faced a $755 million funding gap, according to available data.

    ← Return to text

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.